Abstract
Objective
L-3-[18F]-fluoro-α-methyl tyrosine (18F-FAMT) is an amino acid tracer for positron emission tomography/computed tomography (PET/CT) which specifically transported into cancer cells by L-type amino acid transporter 1 (LAT1). LAT1 overexpression in tumors is significantly correlated with cell proliferation and angiogenesis. 18F-FAMT PET/CT, fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT and magnetic resonance imaging (MRI) were compared for their diagnostic performance in the detection of bone marrow invasion in patients with oral squamous cell carcinoma (OSCC).
Methods
Twenty-seven patients with OSCC on the upper or lower alveolar ridge underwent staging by MRI, 18F-FDG PET/CT and 18F-FAMT PET/CT studies before surgery. Post-surgical pathologic examination was used as the standard to determine the final diagnoses. The possibility of bone marrow invasion on MRI, 18F-FDG PET/CT and 18F-FAMT PET/CT were usually graded retrospectively into five-point score. Sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were calculated according to the obtained scores.
Results
As the sensitivity of 18F-FDG PET/CT was highest (100 %) among that of MRI (95 %) and 18F-FAMT PET/CT (90 %), the specificity of 18F-FAMT PET/CT was highest (85.7 %) among that of MRI (57 %) and 18F-FDG PET/CT (14.3 %). The size of pathological tumor was accorded with that detected by 18F-FAMT PET/CT and was smaller than that detected by 18F-FDG PET/CT (P < 0.01). Significant difference was not found between 18F-FAMT PET tumor volume and pathological tumor volume.
Conclusions
18F-FAMT PET/CT was useful and more specific than MRI or 18F-FDG PET/CT in the detection of bone marrow invasion of OSCC and may contribute to minimize the extent of resection in oral surgery patient.
Similar content being viewed by others
References
Cancer Research UK, International Agency for Research on Cancer. Cancer Stats: Cancer Worldwide. 2011.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck. 2009;31(6):748–58.
Pfister DG, Ang KK, Brizel DM, Burtness BA, Cmelak AJ, Colevas AD, et al. Head and neck cancers. J Natl Compr Canc Netw. 2011;9(6):596–650.
Seitz O, Chambron-Pinho N, Middendorp M, Sader R, Mack M, Vogl TJ, et al. 18F-Fluorodeoxyglucose-PET/CT to evaluate tumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validation with surgical specimen. Neuroradiology. 2009;51(10):677–86.
Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Canc Res. 2007;13(21):6369–78.
Isoda A, Higuchi T, Nakano S, Arisaka Y, Kaira K, Kamio T, et al. (18)F-FAMT in patients with multiple myeloma: clinical utility compared to (18)F-FDG. Ann Nucl Med. 2012;26(10):811–6.
Sun T, Tang G, Tian H, Wang X, Chen X, Chen Z, et al. Radiosynthesis of 1-[18F]fluoroethyl-L-tryptophan as a novel potential amino acid PET tracer. Appl Radiat Isot. 2012;70(4):676–80.
Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, et al. Detection of malignant tumors: whole-body PET with fluorine 18 α-methyl tyrosine versus FDG-preliminary study. Radiology. 2001;220(1):54–62.
Tomiyoshi K, Amed K, Sarwar M, Higuchi T, Inoue T, Endo K, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: Position 2- and 3-L-18F-α-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169–75.
Inoue T, Tomiyoshi K, Higuchi T, Ahmed K, Sarwar M, Aoyagi K, et al. Biodistribution studies on L-3-[Fluorine-18] fluoro-α-methyl tyrosine: a potential tumor detecting agent. J Nucl Med. 1998;39:663–7.
Inoue T, Shibasaki T, Oriuchi N, Aoyagi K, Tomiyoshi K, Amano S, et al. 18F α-methyl Tyrosine PET studies in patients with brain tumors. J Nucl Med. 1999;40:399–405.
Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, et al. Transport of 3-fluoro-L-alpha-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med. 2012;53(8):1253–61.
Ord RA, Sarmadi M, Papadimitrou J. A comparison of segmental and marginal bony resection for oral squamous cell carcinoma involving the mandible. J Oral Maxillofac Surg. 1997;55(5):470–7. discussion 7–8.
Wax MK, Bascom DA, Myers LL. Marginal mandibulectomy vs segmental mandibulectomy: indications and controversies. Arch Otolaryngol Head Neck Surg. 2002;128(5):600–3.
Rajesh A, Khan A, Kendall C, Hayter J, Cherryman G. Can magnetic resonance imaging replace single photon computed tomography and computed tomography in detecting bony invasion in patients with oral squamous cell carcinoma? Br J Oral Maxillofac Surg 2008;46(1):11–4. doi: 10.1016/j.bjoms.2007.08.024.
Sato N, Inoue T, Tomiyoshi K, Aoki J, Oriuchi N, Takahashi A, et al. Gliomatosis cerebri evaluated by 18F alpha-methyl tyrosine positron-emission tomography. Neuroradiology. 2003;45(10):700–7. doi:10.1007/s00234-003-1057-2.
Abd El-Hafez YG, Chen CC, Ng SH, Lin CY, Wang HM, Chan SC, et al. Comparison of PET/CT and MRI for the detection of bone marrow invasion in patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2011;47(4):288–95. doi:10.1016/j.oraloncology.2011.02.010.
Moule RN, Kayani I, Prior T, Lemon C, Goodchild K, Sanghera B, et al. Adaptive 18fluoro-2-deoxyglucose positron emission tomography/computed tomography-based target volume delineation in radiotherapy planning of head and neck cancer. Clin Oncol (R Coll Radiol). 2011;23(5):364–71. doi:10.1016/j.clon.2010.11.001.
Miyakubo M, Oriuchi N, Tsushima Y, Higuchi T, Koyama K, Arai K, et al. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET. Ann Nucl Med. 2007;21(2):129–35.
Imaizumi A, Yoshino N, Yamada I, Nagumo K, Amagasa T, Omura K, et al. A potential pitfall of MR imaging for assessing mandibular invasion of squamous cell carcinoma in the oral cavity. AJNR Am J Neuroradiol. 2006;27(1):114–22.
van den Brekel MW, Runne RW, Smeele LE, Tiwari RM, Snow GB, Castelijns JA. Assessment of tumour invasion into the mandible: the value of different imaging techniques. Eur Radiol. 1998;8(9):1552–7.
Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104(2):238–53. doi:10.3171/jns.2006.104.2.238.
Hong R, Halama J, Bova D, Sethi A, Emami B. Correlation of PET standard uptake value and CT window-level threshold for target delineation in CT-based radiation treatment planning. Int J Radiat Oncol Biol Phys. 2007;67(3):720–6. doi:10.1016/j.ijrobp.2006.09.039.
Wong RJ. Current status of FDG-PET for head and neck cancer. J Surg Oncol. 2008;97:649–52.
Xu G, Li J, Zuo X, Li C. Comparison of whole body positron emission tomography (PET)/PET-computed tomography and conventional anatomic imaging for detecting malignancies in patients with head and neck cancer: a meta-analysis. Laryngoscope. 2012;122:1974–8.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, M., Higuchi, T., Arisaka, Y. et al. Clinical significance of 18F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with 18F-FDG PET/CT and MRI. Ann Nucl Med 27, 423–430 (2013). https://doi.org/10.1007/s12149-013-0701-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-013-0701-0